Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.
Immunomedics, Inc.
A C A C A C C A C C C C C C A A C C C C C C A C A A A C A
A61K C07K A61K C07K A61K C07K C07K A61K C07K C07K C07K C07K C07K C07K A61K A61K C07K C07K C07K C07K C07K C07K A61K C07K A61K A61K A61K C07K A61K
inventional inventional inventional inventional inventional inventional inventional inventional additional additional additional inventional inventional additional inventional inventional inventional inventional additional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Chien-Hsing David M.
Chang Goldenberg